McNamara R L, Lima J A, Whelton P K, Powe N R
Johns Hopkins Medical Institutions, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland, USA.
Ann Intern Med. 1997 Nov 1;127(9):775-87. doi: 10.7326/0003-4819-127-9-199711010-00001.
No consensus exists about the use of imaging strategies to identify potential cardiovascular sources of emboli in patients who have had strokes.
To determine the cost-effectiveness of various cardiac imaging strategies after stroke.
A markov model decision analysis was used to evaluate the benefits and costs of nine diagnostic strategies, including transthoracic echocardiography, transesophageal echocardiography, sequential approaches, selective imaging, and no imaging.
Simulated clinical practice in the United States.
Hypothetical patients with a first stroke who were in normal sinus rhythm.
Echocardiographic detection rates of potential sources of emboli were ascertained by doing a systematic review of the literature. Values for event rates, anticoagulation effects, utilities, and costs were obtained from the literature and Medicare data.
When visualized left atrial thrombus was used as the only indication for anticoagulation, transesophageal echocardiography performed only in patients with a history of cardiac problems cost $9000 per quality-adjusted life-year; transesophageal echocardiography in all patients cost $13,000 per quality-adjusted life-year. Cost savings and decreased morbidity and mortality rates associated with reduction in preventable recurrent strokes substantially offset examination costs and risks of anticoagulation. These results were moderately sensitive to efficacy of anticoagulation and incidence of intracranial bleeding during anticoagulation and were mildly sensitive to prevalence of left atrial thrombus, rate of recurrent stroke in patients with thrombus, quality of life after stroke, cost of transesophageal echocardiography, and specificity of transesophageal echocardiography. Transthoracic echocardiography, alone or in sequence with transesophageal echocardiography, was not cost-effective compared with transesophageal echocardiography.
Physicians should consider doing transesophageal echocardiography in all patients with new-onset stroke.
对于采用影像学策略来识别中风患者潜在的心血管栓子来源,目前尚无共识。
确定中风后各种心脏成像策略的成本效益。
采用马尔可夫模型决策分析来评估九种诊断策略的益处和成本,包括经胸超声心动图、经食管超声心动图、序贯方法、选择性成像以及不进行成像。
美国的模拟临床实践。
首次中风且处于正常窦性心律的假设患者。
通过对文献进行系统回顾来确定超声心动图对潜在栓子来源的检测率。事件发生率、抗凝效果、效用值和成本值均从文献和医疗保险数据中获取。
当将可视化左心房血栓作为抗凝的唯一指征时,仅对有心脏问题病史的患者进行经食管超声心动图检查,每质量调整生命年的成本为9000美元;对所有患者进行经食管超声心动图检查,每质量调整生命年的成本为13000美元。与可预防的复发性中风减少相关的成本节约以及发病率和死亡率的降低,在很大程度上抵消了检查成本和抗凝风险。这些结果对抗凝疗效和抗凝期间颅内出血发生率具有中等敏感性,对左心房血栓的患病率、有血栓患者的复发性中风发生率、中风后的生活质量、经食管超声心动图检查成本以及经食管超声心动图检查的特异性具有轻度敏感性。与经食管超声心动图相比,单独使用经胸超声心动图或与经食管超声心动图序贯使用均不具有成本效益。
医生应考虑对所有新发中风患者进行经食管超声心动图检查。